Dassault to enhance clinical tech with $5.8bn Medidata acquisition
Product lifecycle management company Dassault Systèmes has announced it will acquire clinical cloud...
Focus:
-
![virtual clinical trials]()
Medidata: moving towards virtualised, patient-centric trials
-
![pembrolizumab head and neck cancer]()
Pembrolizumab trumps chemotherapy in recurrent head and neck cancer
-
![Lynparza BRCA panceratic cancer]()
Lynparza reduces PFS in germline BRCA-mutated pancreatic cancer
-
![combination asthma drug]()
Novartis’ IND/MF drug achieves endpoints in Phase III study
-
![triple combination multiple myeloma]()
Triple combination more efficacious in newly diagnosed multiple myeloma
-
![Piqray PIK3CA mutation]()
FDA approves Novartis’ Piqray as the first drug targeting PIK3CA mutation
Most Read
- Dassault to enhance clinical tech with $5.8bn Medidata acquisition
- Medidata: moving towards virtualised, patient-centric trials
- Pembrolizumab trumps chemotherapy in recurrent head and neck cancer
- Lynparza reduces PFS in germline BRCA-mutated pancreatic cancer
- Novartis’ IND/MF drug achieves endpoints in Phase III study
Company A-Z
Latest Content
Brodalumab shows promise in Axial Spondyloarthritis with strong Phase III results
Of the 80 participants enrolled in the brodalumab arm, 17 were diagnosed with non-radiographic axial spondyloarthritis (nr-axSpA), and 36% of nr-axSpA achieved ASAS40.
Positive results reported for Eli Lilly’s ultra-rapid insulin
Positive results indicate that ultra-rapid lispro (URLi) is shaping out to be a promising new option for diabetes patients who require mealtime insulin.
Erleada looks to advance treatment of metastatic hormone-sensitive prostate cancer paradigm
ASCO 2019 discusses several prostate cancer trials of second-generation hormonal agents, including the SPARTAN, ENZAMET and TITAN trials.
Eli Lilly is likely to establish Emgality in the preventative migraine market
Emgality is a humanised mAb that binds and inhibits the activity of CGRP and is administered via subcutaneous injection once per month. Eli Lilly’s extensive experience with commercialising products in the neurology market will also help establish Emgality in the migraine market.
Dassault to enhance clinical tech with $5.8bn Medidata acquisition
Product lifecycle management company Dassault Systèmes has announced it will acquire clinical cloud solution provider Medidata Solutions in an all-cash transaction.
Approval for Piqray, the first PI3K inhibitor in the treatment of breast cancer
Piqray occupies a strong position in the metastatic setting for patients harbouring a PI3KCA mutation.
Novel HER2 blockade treatments continue to show promise in third-line setting for metastatic breast cancer
Patients with HER2-positive metastatic breast cancer continue to need new treatment options.
Takeda’s Ninlaro fails in Phase III trial for treatment of amyloidosis
Despite being a successful treatment for multiple myeloma since it was first approved, the Phase III trial result is a setback for Takeda's Ninlaro. Takeda is investigating the combination of Ninlara and chemotherapy for AL amyloidosis and this combination is currently in Phase II trials with results expected next year.
Maintenance olaparib trial brings hope to BRCA mutant pancreatic cancer patients
In pancreatic cancer, no targeted treatments for a biomarker selected population had been validated in a Phase III trial.
Medidata: moving towards virtualised, patient-centric trials
At its London NEXT conference, Medidata representatives discussed how technology will transform the future of clinical trials. One of the ways that the company sees clinical development advancing in the coming years is though a virtual and patient-centric approach, and therefore Medidata is seeking to get ahead of the curve by starting to implement these theories into its strategies and platform.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Close
Close
Close
Go Top
